3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Sarcoma, Endometrial Stromal
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Neoplasms
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Adenosarcoma of the uterus
1
Interventions
Biopsy
5
X-Rays
4
Specimen Handling
4
Phantoms, Imaging
4
Nuclear Medicine Department, Hospital
4
Magnetic Resonance Spectroscopy
4
Carboplatin
3
larotrectinib
2
erdafitinib
2
ensartinib
2
cabozantinib
2
Topotecan
2
Temozolomide
2
Etoposide
2
Cyclophosphamide
2
Cisplatin
2
ulixertinib
1
tipifarnib
1
tazemetostat
1
selpercatinib
1
pegfilgrastim
1
palbociclib
1
olaparib
1
niraparib
1
mirdametinib
1
ivosidenib
1
irinotecan sucrosofate
1
entrectinib
1
elacestrant
1
budigalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
RAD1901
×
30 days
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled